Editas Medicine: Business Highlights and Financial Results Reported

Editas Medicine Reporting
Editas Medicine (EDIT) reported business highlights and financial results for the first quarter of 2021. The reporting started with James C. Mullen, Chairman, President and Chief Executive Officer, Editas Medicine stating that Editas’ team is making tremendous progress towards discovering, developing, and manufacturing novel genome editing medicines, including excellent forward momentum this quarter for the firm’s two . . .

This content is for paid subscribers.
Please click here to subscribe or here to log in.